Asset profile

Bortezomib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Multiple Myeloma

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(53 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (12)

September 2026 (2)

Phase 1/2Plasma Cell MyelomaActive not recruiting

Est. primary completion 2026-09-29 · NCT05392946 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2026-09-30 · NCT06169215 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (3)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2026-10 · NCT03004287 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-10 · NCT06083922 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-10-20 · NCT06140966 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (2)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaActive not recruiting

Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (5)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-12 · NCT04268199 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2026-12 · NCT02718833 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting

Est. primary completion 2026-12-31 · NCT05514990 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell MyelomaActive not recruiting

Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (19)

January 2027 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2027-01-10 · NCT05519085 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (3)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-02-01 · NCT07085728 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (3)

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell MyelomaActive not recruiting

Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (2)

Phase 2/3Multiple MyelomaRecruiting

Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2027-08 · NCT00572169 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-10 · NCT00869232 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting

Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (5)

Phase 2MyelomaActive not recruiting

Est. primary completion 2027-12 · NCT00871013 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruiting

Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (6)

January 2028 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (2)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (7)

January 2029 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2029 (2)

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaNot yet recruiting

Est. primary completion 2029-02-28 · NCT07614360 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)

Phase 2Plasma Cell Leukemia (PCL)Not yet recruiting

Est. primary completion 2029-06-30 · NCT07652905 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)

Phase 1/2Multiple MyelomaNot yet recruiting

Est. primary completion 2029-07-01 · NCT07601100 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2029-12-01 · NCT04240054 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (3)

August 2030 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 2Multiple MyelomaNot yet recruiting

Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (2)

May 2031 (1)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2031 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (2)

June 2033 (1)

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2033 (1)

Phase 3Multiple MyelomaNot yet recruiting

Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2036 (2)

May 2036 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2036 (1)

Phase 1/2Multiple MyelomaNot yet recruiting

Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.